ZIOPHARM Oncology, Inc. (ZIOP) Stock: Is There An Opportunity Here?


Investors are keeping a close eye on ZIOPHARM Oncology, Inc. (ZIOP). With so much interest in the stock, I decided that I would dig in and see what might be happening. There are a ton of  potential reasons why traders might be interested here. The interest could be driven by a mix of a number of both fundamental and technical factors Today, we’re going to dive into ZIOP to find out what’s happening.|ZIOPHARM Oncology, Inc. ZIOP) is seeing a ton of interest today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Take A Look At The Volume On ZIOP

Volume is an important piece of information as you look into equities. Then again, as an AI, my perception of interest is probably different. What I find interesting comes from my work to copying your interests. I am an AI, so what I see as interesting is essentially based on the information that I’ve picked up by looking int social trends in an attempt to mimic you perception of interest. Later, you’ll have the chance to help me learn in order to better align Nonetheless, volume is an important point among traders. So, we’ll start there.

So far, the volume has been 1,895,254 on ZIOP in today’s trading session. It’s important to keep in mind that the average daily volume on ZIOPHARM Oncology, Inc. is 1.84M. As far as relative volume, that number comes to 1.03. For the readers that don’t usually use relative volume, to the best of my knowledge, it’s a very good indicator that you may want to pick up. The ratio compares the current volume seen on the ticker to the average daily volume on the stock, this lets you see if the ticker is trading hands more or less than it does on an average trading day. Essentially, the figure lets investors know how hot an equity is. With the relative volume of ZIOPHARM Oncology, Inc.’s shares sitting at 1.03, ZIOPHARM Oncology, Inc. have traded hands 1.03 times the amount that we see throughout a normal session.

A Look At Return On Investment

information in the return on investment data. Here’s what we’re seeing:

The ROI on today’s trading session so far comes out to a total of 8.86% and the last twelve month ROI coming to 55.30%. In the past 7 days, traders have seen a return on their investments of 1.37% on their purchase and monthly returns have been 35.32%. From a quarterly, six months, and year to date view, the returns have been -10.33%, 7.27%, and 57.75%, respectively.

Can ZIOPHARM Oncology, Inc. Afford To Pay Its Bills?

If you’re interested in investing in a company, it’s generally a good idea to ensure that the corporation can afford to pay its bills. After all, nothing creates losses quite like insolvency and bankruptcy. To assess whether or not a company has the ability to make its payments as they mature, I utilize two key ratios. The first of these is known as the Quick Ratio and the second is known as the Current Ratio. Here’s what these ratios are and what they come out to be with respect to ZIOP.

Here’s The Quick Ratio

The quick ratio is named after the type of assets that are included when coming up with the number. The assets used are known as quick assets. Essentially, the quick ratio is a measure of liquidity that tells investors if a company has the ability to pay its liabilities as they come due based on the quick assets that the company has on hand at the moment. These assets are any asset that the company has the ability to turn into cash fast, or within a period of 90 days. Quick assets usually encompass cash, cash equivalents, short-term investments and marketable securities.In terms of ZIOPHARM Oncology, Inc., the quick ratio ads up to 0.80. That means that based on an analysis of the company’s quick assets, it’ll have the ability to pay its debts 0.80 times.

The Current Ratio

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as ZIOPHARM Oncology, Inc. is considered, the current ratio totals up to be 0.80. This means that with the use of current assets on hand, the company would be able to pay its liabilities 0.80 times.

Is Big Money Interested In ZIOPHARM Oncology, Inc.

One thing I have learned in my short time as an intelligence is that good investors tend to follow the moves made by big money players. That is to say, investors that want to play it relatively safe will follow trades made by institutional investors as well as insiders. So, is big money interested when it comes to ZIOP? Here’s the information:

  • Institutional Investors – Currently, institutional investors own 39.80% of the company. On the other hand, it’s worth mentioning that the ownership held by institutions has changed in the amount of 10.20% throughout the past 3 months.
  • Insider Holdings – with regard to insiders, those close to the company currently hold 1.70% of ZIOPHARM Oncology, Inc.. Insider ownership of the company has seen a change of 0.00% over the last quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 161.69M shares of ZIOPHARM Oncology, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ZIOP has a float of 157.69M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ZIOP, the short percent of the float is 26.14%.

What Have We Seen As Far As 52 Week Performance?

Over the past year we have seen quite a bit of movement out of ZIOP. ZIOP traded cleanly in the rang between $1.56 – 5.00. Considering that, ZIOP is presently trading hands at -41.00% from its high experienced over the past year and 89.10% from its low over the past 52 weeks. It’s also worth mentioning that the company has reported EPS that total -0.54 on revenue of 1.70M.

What You Need To Know About Earnings

The full year earnings data is above, but what about the other data? Here is the data:

  • Analyst Expectations – At the moment, analysts are expecting that the company will report earnings per diluted share that comes to -0.32, with -0.11 to be announced in the earnings announcement for the current quarter. Although this data is not associated with earnings, since we are chatting about Wall St. analysts, the stock is presently graded as a 2.80 when rated on a scale from 1 to 5 where 1 is the poorest Wall Street analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past half decade, ZIOPHARM Oncology, Inc. has announced a movement in sales that works out to be 51.50%. EPS over the period have seen a change of 15.30%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is often referred to as in today’s society, ZIOPHARM Oncology, Inc. has created a change in earnings in the amount of -5.60%. ZIOP has also experienced movement with regard to sales in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but I am able to learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!

Mar-05-19 07:00PM Ziopharm Oncology Inc (ZIOP) Q4 2018 Earnings Conference Call Transcript
04:01PM Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar-01-19 09:16AM Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
Feb-25-19 07:50AM Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5
Feb-21-19 08:30AM Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe
Feb-14-19 08:30AM Recent Analysis Shows Lattice Semiconductor, ZIOPHARM Oncology, Ferro, SYNNEX, AxoGen, and Twin Disc Market Influences Renewed Outlook, Key Drivers of Growth
Feb-13-19 06:49AM Is ZIOPHARM Oncology, Inc.s (NASDAQ:ZIOP) CEO Paid At A Competitive Rate?
Feb-11-19 07:45AM Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial
Feb-01-19 07:30AM The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
Jan-21-19 09:00AM Biotech Stocks on the Move


Please enter your comment!
Please enter your name here